BioTime touts early results of research on iPS cell technology

03/16/2010 | Wall Street Journal, The · Bloomberg Businessweek

Preliminary data show that one of the six lines of induced pluripotent stem cells being studied by BioTime had enough of the protein telomerase to reverse cellular aging, making the iPS cell line a potential alternative to embryonic stem cells. BioTime CEO Michael West expressed optimism that the company is "years away -- not decades away -- from clinical trials."

View Full Article in:

Wall Street Journal, The · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX